CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis

Area of Science:

• Gastroenterology
• Immunology
• Cell Biology

Background:

• Ulcerative colitis involves gut inflammation and barrier dysfunction.
• CXC chemokine receptor 4 (CXCR4) antagonists show promise in reducing colitis.
• The specific effects of CXCR4 antagonists on the intestinal barrier remain unclear.

Purpose of the Study:

• To investigate the impact of CXCR4 antagonist AMD3100 on intestinal barrier function in experimental colitis.
• To elucidate the potential mechanisms underlying AMD3100's effects on the colonic barrier.

Main Methods:

• Experimental colitis induced using dextran sulfate sodium (DSS) in mice.
• AMD3100 administered intraperitoneally daily.
• In vitro studies using HT-29/B6 colonic cells treated with cytokines and/or AMD3100.
• Assessment of disease activity, intestinal permeability, and claudin expression.

Main Results:

• AMD3100 significantly reduced colonic inflammation, epithelial damage, and disease activity in DSS-induced colitis.
• AMD3100 treatment restored intestinal barrier integrity by normalizing claudin expression.
• In vitro, cytokines increased apoptosis and permeability, while AMD3100 mitigated these effects, partly via a cytokine-dependent pathway.

Conclusions:

• AMD3100 effectively ameliorates DSS-induced colitis and enhances intestinal barrier function.
• The protective effects of AMD3100 involve the modulation of colonic claudin expression.
• AMD3100's mechanism may be linked to cytokine-dependent pathways influencing barrier integrity.